HUP9900227A2 - New pharmacological use of aii-receptor antagonists - Google Patents

New pharmacological use of aii-receptor antagonists

Info

Publication number
HUP9900227A2
HUP9900227A2 HU9900227A HUP9900227A HUP9900227A2 HU P9900227 A2 HUP9900227 A2 HU P9900227A2 HU 9900227 A HU9900227 A HU 9900227A HU P9900227 A HUP9900227 A HU P9900227A HU P9900227 A2 HUP9900227 A2 HU P9900227A2
Authority
HU
Hungary
Prior art keywords
receptor antagonists
aii
mof
general formula
treatment
Prior art date
Application number
HU9900227A
Other languages
Hungarian (hu)
Inventor
Anders Aneman
Lars Fändriks
Anders Pettersson
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of HUP9900227A2 publication Critical patent/HUP9900227A2/en
Publication of HUP9900227A3 publication Critical patent/HUP9900227A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány tárgyát (I) általánős képletű angiőtenzin II 1 típűsú-receptőr antagőnisták többszörös szervrendszeri elégtelenség (műltiplesystem őrgan failűre; MOF) megelőzésére és/vagy kezelésére, és a MOFkezelésében hatásős gyógyszerkészítmények előállítására valófelhasználása képezi. Az (I) általánős képletű ismert antagőnistákközül különösen előnyös a lősartan[A = (I.1)] és a candesartanciletexil (TCV-116)[A = (I.5)] generikűs nevű hatóanyag. Azantagőnistákat semleges vagy só főrmában, racem keverékként vagytiszta enantiőmerként használják előnyösen injekciós gyógyszerfőrmákelőállítására, de őrális és rektális adagőlású készítmények iselőállíthatók. ŕThe subject of the invention is the use of angiotensin II type 1 receptor antagonists of general formula (I) for the prevention and/or treatment of multiple organ system failure (multiple system organ failure; MOF) and for the production of pharmaceutical preparations effective in the treatment of MOF. Among the known antagonists with the general formula (I), the active substances with the generic names lõsartan [A = (I.1)] and candesartan ciletexil (TCV-116) [A = (I.5)] are particularly preferred. Azanthine crystals are preferably used in neutral or salt form, as a racemic mixture or as a pure enantiomer for the production of injectable drug forms, but preparations for oral and rectal administration can also be produced. ŕ

HU9900227A 1995-05-19 1996-05-08 New pharmacological use of aii-receptor antagonists HUP9900227A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501881A SE9501881D0 (en) 1995-05-19 1995-05-19 New pharmacological use of AII receptor antagonists
PCT/SE1996/000602 WO1996036336A1 (en) 1995-05-19 1996-05-08 New pharmacological use of aii-receptor antagonists

Publications (2)

Publication Number Publication Date
HUP9900227A2 true HUP9900227A2 (en) 2000-03-28
HUP9900227A3 HUP9900227A3 (en) 2002-11-28

Family

ID=20398385

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900227A HUP9900227A3 (en) 1995-05-19 1996-05-08 New pharmacological use of aii-receptor antagonists

Country Status (23)

Country Link
US (1) US5900428A (en)
EP (1) EP0830131A1 (en)
JP (1) JPH11505243A (en)
KR (1) KR19990014905A (en)
CN (1) CN1093761C (en)
AU (1) AU706301B2 (en)
BR (1) BR9608407A (en)
CA (1) CA2219395A1 (en)
CZ (1) CZ290155B6 (en)
EE (1) EE03666B1 (en)
HU (1) HUP9900227A3 (en)
IL (1) IL118299A (en)
IS (1) IS4597A (en)
MX (1) MX9708557A (en)
MY (1) MY114428A (en)
NO (1) NO975221L (en)
NZ (1) NZ308260A (en)
RU (1) RU2194505C2 (en)
SE (1) SE9501881D0 (en)
SK (1) SK151397A3 (en)
TW (1) TW473389B (en)
WO (1) WO1996036336A1 (en)
ZA (1) ZA963569B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
US6514249B1 (en) 1997-07-08 2003-02-04 Atrionix, Inc. Positioning system and method for orienting an ablation element within a pulmonary vein ostium
SE9800550D0 (en) * 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
ES2274625T3 (en) 1998-05-18 2007-05-16 Takeda Pharmaceutical Company Limited REMOVABLE TABLETS IN THE MOUTH THAT INCLUDE A BENCIMIDAZOL.
AU4802099A (en) 1998-07-28 2000-02-21 Takeda Chemical Industries Ltd. Rapidly disintegrable solid preparation
EP1262180A4 (en) 2000-02-18 2005-06-01 Takeda Pharmaceutical Tnf-alpha inhibitors
JP4880591B2 (en) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド Pharmaceutical composition comprising irbesartan
KR20130074808A (en) 2011-12-16 2013-07-05 한올바이오파마주식회사 The pharmaceutical composition comprising losartan for treating or preventing statin-induced muscle toxicity
CN104261284B (en) * 2014-09-18 2016-02-03 中邮建技术有限公司 A kind of antenna hanging apparatus of wireless base station
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides

Also Published As

Publication number Publication date
IL118299A (en) 2000-07-26
CN1093761C (en) 2002-11-06
US5900428A (en) 1999-05-04
TW473389B (en) 2002-01-21
NZ308260A (en) 2000-12-22
CZ345497A3 (en) 1998-03-18
HUP9900227A3 (en) 2002-11-28
CA2219395A1 (en) 1996-11-21
RU2194505C2 (en) 2002-12-20
CZ290155B6 (en) 2002-06-12
NO975221D0 (en) 1997-11-13
IS4597A (en) 1997-10-22
JPH11505243A (en) 1999-05-18
MY114428A (en) 2002-10-31
EP0830131A1 (en) 1998-03-25
EE03666B1 (en) 2002-04-15
BR9608407A (en) 1998-12-29
SE9501881D0 (en) 1995-05-19
KR19990014905A (en) 1999-02-25
AU5784596A (en) 1996-11-29
ZA963569B (en) 1996-11-19
MX9708557A (en) 1997-12-31
SK151397A3 (en) 1998-08-05
WO1996036336A1 (en) 1996-11-21
AU706301B2 (en) 1999-06-10
EE9700309A (en) 1998-06-15
NO975221L (en) 1997-11-13
IL118299A0 (en) 1996-09-12
CN1184424A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
DK0668863T3 (en) Quinuclidine derivative as substance P antagonist
NO306457B1 (en) 2,4-disulfonylphenylbutylnitron, salts thereof, pharmaceutical composition, and the use of this compound in the manufacture of a medicament
CY1112260T1 (en) CONTROLLED HYDROCONUT PACKAGES
HUP0400475A2 (en) Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof
LU91037I2 (en) Somatulina autogel
ES2052717T3 (en) USE OF INDOLONE DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF PARKINSON'S DISEASE.
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
ATE315379T1 (en) DRUGS FOR THE CONTROLLED RELEASE OF BETA LACTAM ANTIBIOTICS
HUP0101411A2 (en) A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
KR960700061A (en) PHARMACEUTICAL COMPOSITION FOR TREATING NICOTINE DEPENDENCE
MY121831A (en) Pharmaceutical combination preparations in solid dosage form of carvedilol and hydrochlorothiazide
HUP9900227A2 (en) New pharmacological use of aii-receptor antagonists
RU93047023A (en) ANIMOTENZINE-11 IMIDAZOLE ANTAGONISTS DERIVATIVES, THEIR PRODUCTION AND THERAPEUTIC USE
NO974400L (en) Combination preparations containing benazepril or benazeprilat and valsartan
HUP9901208A2 (en) (r)-5-bromo-n-(1-ethyl-4-methylhexahydro-1h-1,4-diazepin-6-yl)-2-methoxy-6-methyl-amino-3-pyridine-carboxamide, process for producing the same and medicinal composition containing the same
HUP9702448A2 (en) Pharmaceutical composition for parenteral application containing an indole-carboxylic acid
DE59910944D1 (en) TRANSDERMAL THERAPEUTIC SYSTEM FOR THE USE OF CANDESARTAN
GEP20043377B (en) Pharmaceutical Complex
DE69803670T2 (en) MEDICINE PREPARATIONS WITH TIAGABINE WITH CONTROLLED ACTIVE SUBSTANCE ADMINISTRATION
DE50010973D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DESOXYPEGANINE FOR THE TREATMENT OF ALCOHOLISM
DE60007074D1 (en) SULFATED PHOSPHATIDYLINOSITOLS, THEIR PRODUCTION AND USE
DE69318715D1 (en) PHARMACOLOGICALLY ACTIVE ALPHA- (TERTIARY-AMINOETHYL) -PHENYLMETHANOL DERIVATIVES
BG108144A (en) New use
HUP9701284A2 (en) Use of 2,3-benzodiazepine derivatives for producing pharmaceutical compositions for treating and prophylacting illnesses and conditions connected with the endogene opioide system
EA200100982A1 (en) Polymorph CRYSTALLINE CITRATE (2-benzhydryl-1-azabicyclo [2.2.2] oct-3-yl) - (5-isopropyl-2-methoxybenzyl) -amine as antagonists of the neurokinin 1 (NK1)